These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17084074)

  • 1. Targeting ubiquitin in cancers.
    Dikic I; Crosetto N; Calatroni S; Bernasconi P
    Eur J Cancer; 2006 Dec; 42(18):3095-102. PubMed ID: 17084074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the ubiquitin/proteasome system in cellular responses to radiation.
    McBride WH; Iwamoto KS; Syljuasen R; Pervan M; Pajonk F
    Oncogene; 2003 Sep; 22(37):5755-73. PubMed ID: 12947384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Cusack JC; Liu R; Xia L; Chao TH; Pien C; Niu W; Palombella VJ; Neuteboom ST; Palladino MA
    Clin Cancer Res; 2006 Nov; 12(22):6758-64. PubMed ID: 17121896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
    Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future novel single agent and combination therapies.
    Cirstea D; Vallet S; Raje N
    Cancer J; 2009; 15(6):511-8. PubMed ID: 20010171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting strategies in cancer gene therapy.
    Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):311-6. PubMed ID: 12673383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 14. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.
    Motegi A; Murakawa Y; Takeda S
    Cancer Lett; 2009 Sep; 283(1):1-9. PubMed ID: 19201084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating bortezomib into the treatment of lung cancer.
    Davies AM; Lara PN; Mack PC; Gandara DR
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ubiquitin- and Ubl-binding proteins in cell signaling.
    Kirkin V; Dikic I
    Curr Opin Cell Biol; 2007 Apr; 19(2):199-205. PubMed ID: 17303403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
    Wright JJ
    Clin Cancer Res; 2010 Aug; 16(16):4094-104. PubMed ID: 20682705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.